Ana Newnam
About Ana Newnam
Ana Newnam is the Executive Director of Oncology CI at Bristol Myers Squibb, with extensive experience in strategic insights and competitive intelligence across multiple therapeutic areas.
Company
Ana Newnam is currently working at Bristol Myers Squibb in New Jersey, United States. She holds the roles of Executive Director, Oncology CI in New Jersey, Director, Oncology CI in Princeton, NJ, and AD, WW GU & GI CI in Princeton, NJ. Bristol Myers Squibb is a global biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for patients with serious diseases.
Title
Ana Newnam holds the position of Executive Director, Oncology CI at Bristol Myers Squibb. In her capacity, she is responsible for leading and managing competitive intelligence operations for the oncology division.
Education and Expertise
Ana Newnam holds an MBA in Marketing from Rider University and a BA in Economics from Rutgers University. She has extensive experience in various therapeutic areas, including immuno-oncology, ophthalmology, endocrinology/diabetes, dermatology, infectious diseases, pain, men's and women's health, urology, CNS, and organ transplants.
Background
Ana Newnam has had a diverse and comprehensive career in strategic insights and competitive intelligence. She worked as a Strategic Insights Consultant at Novo Nordisk, Director of Strategic Insights at Valeant Pharmaceuticals, and SR MGR, MKT RESEARCH - HIV at Johnson & Johnson. Additionally, she has held positions as Director at Adelphi Research by Design and NOP World, MR Analyst/Project Director at Research Connections, Strategic Intelligence Analyst/Brand Planner at J. Walter Thompson, and Analyst at GfK Market Measures.
Achievements
During her tenure at Bristol Myers Squibb, Ana Newnam led the development of interactive key competitor dashboards and a landscape timeline tool. She spearheaded congress optimization initiatives to drive enterprise performance. Ana has a notable commitment to patient safety and public health, having administered three legacy Celgene REMS programs, developed a risk management system for thalidomide, and implemented controls for the distribution of Revlimid® and Pomalyst®. She has also been recognized for building, managing, training, and mentoring high-performing competitive intelligence teams.